RA Capital, a 10% Owner and Director, Makes Substantial $172M Post-IPO Investment in Hemab Therapeutics
Summary
RA Capital Healthcare Fund LP, a 10% owner and director, significantly increased its stake in Hemab Therapeutics Holdings, Inc. with over $172 million in combined open market purchases and preferred stock conversions following the company's recent IPO.
Key Events
-
Significant Insider Investment
RA Capital Healthcare Fund LP, a 10% owner and director, acquired shares totaling over $172 million through a combination of open market purchases and preferred stock conversions.
-
Post-IPO Confidence
The transactions include open market purchases of common stock valued at over $52 million, with prices ranging from the IPO price of $18.00 up to $25.00 per share, demonstrating conviction above the initial offering price.
-
Timing After Upsized IPO
These transactions occurred between May 4-6, 2026, immediately following Hemab Therapeutics' recently completed upsized initial public offering, which was priced at $18.00 per share.
Analysis
This Form 4 filing indicates a strong vote of confidence from RA Capital Healthcare Fund LP, a major institutional investor with board representation, in Hemab Therapeutics Holdings, Inc. The combined open market purchases and preferred stock conversions, totaling over $172 million, represent a substantial investment following the company's recent upsized IPO. The open market purchases, some made above the IPO price, suggest that RA Capital sees significant value in the company post-listing. This large insider buying activity from a key investor and director group could be interpreted positively by the market, signaling strong conviction in Hemab's future prospects.
At the time of this filing, COAG was trading at $24.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $23.48 to $32.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.